{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:37Z","timestamp":1761178597518,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.canrad.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:59:41Z","timestamp":1696946381000},"page":"731-735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-2383","authenticated-orcid":false,"given":"A.","family":"Kahvecioglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.06.002_bib0105","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer","volume":"34","author":"Gadgeel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.06.002_bib0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain metastases in EGFR- and ALK-Positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2023.06.002_bib0115","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.06.002_bib0120","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s11999-010-1326-4","article-title":"In brief: classifications in brief: Mirels\u2019 classification: metastatic disease in long bones and impending pathologic fracture","volume":"468","author":"Jawad","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.canrad.2023.06.002_bib0125","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.06.002_bib0130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/cancers7020763","article-title":"Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer","volume":"7","author":"Isozaki","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canrad.2023.06.002_bib0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.002_bib0140","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.06.002_bib0145","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2023.06.002_bib0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: an ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.002_bib0155","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III Trial NRG Oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.06.002_bib0160","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.2147\/CMAR.S190098","article-title":"The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis","volume":"11","author":"Hou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.canrad.2023.06.002_bib0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.canrad.2023.06.002_bib0170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.lungcan.2015.03.022","article-title":"Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for disease assessment and management","volume":"88","author":"Ou","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2023.06.002_bib0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13691-015-0231-9","article-title":"Marked improvement in leptomeningeal carcinomatosis and spinal cord metastases following alectinib treatment of crizotinib-resistant, ALK-positive lung adenocarcinoma","volume":"5","author":"Kuribayashi","year":"2016","journal-title":"Int Cancer Conf J"},{"key":"10.1016\/j.canrad.2023.06.002_bib0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2016.03.008","article-title":"Alectinib induced CNS radiation necrosis in an ALK\u00a0+\u00a0NSCLC patient with a remote (7\u00a0years) history of brain radiation","volume":"96","author":"Ou","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2023.06.002_bib0185","first-page":"29","article-title":"Alectinib treatment of ALK positive non-small cell lung cancer patients with brain metastases: our clinical experience","volume":"41","author":"Crvenkova","year":"2020","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"key":"10.1016\/j.canrad.2023.06.002_bib0190","first-page":"e35952","article-title":"Symptomatic brain radiation necrosis in an anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patient after fractionated stereotactic radiotherapy while on alectinib","volume":"15","author":"BalajiSubramanian","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.canrad.2023.06.002_bib0195","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.lungcan.2022.11.019","article-title":"Multicenter analysis of stereotactic radiosurgery for multiple brain metastases from EGFR and ALK driven non-small cell lung cancer","volume":"176","author":"Wandrey","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2023.06.002_bib0200","first-page":"94","article-title":"Alectinib and brigatinib: new second-generation ALK inhibitors for the treatment of non-small cell lung cancer","volume":"9","author":"Beardslee","year":"2018","journal-title":"J Adv Pract Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823001130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823001130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:37:32Z","timestamp":1761136652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823001130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1278321823001130"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.06.002","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}]}}